|Mr. Lawrence Mehren||Chief Exec. Officer, Pres and Director||360.58k||N/A||52|
|Mr. Steve Reichling||Chief Financial Officer, Chief Accounting Officer and Sec.||230.38k||N/A||40|
|Mr. Kurt Reinhardt||Head of Operations||N/A||N/A||N/A|
|Dr. Romney M. Humphries Ph.D., D(ABMM), M (ASCP)CM||Chief Scientific Officer||N/A||N/A||N/A|
|Mr. Steven W. Metzger||Head of Discovery & New Products||N/A||N/A||44|
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
Accelerate Diagnostics, Inc.’s ISS Governance QualityScore as of January 1, 2018 is 6. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 2; Compensation: 7.